Market Overview

Option Care Health Announces Third Quarter Results


BANNOCKBURN, Ill., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Option Care Health, Inc. (NASDAQ:BIOS), the nation's largest independent provider of home and alternate site infusion services, today announced financial results for the third quarter ended September 30, 2019.

Transaction Highlights

  • Completed merger between legacy Option Care Enterprises, Inc. ("Option Care") and BioScrip, Inc. ("BioScrip") organizations on August 6, 2019 to create Option Care Health, Inc. ("Option Care Health" or the "Company")

  • Established new Executive Leadership Team and broader field and functional leadership of the Company, retaining key talent across both legacy organizations

  • Achieved significant progress in integrating commercial organizations and optimizing commercial resource deployment

  • Initiated integration efforts across procurement strategies, field resource optimization and spending reduction initiatives

John C. Rademacher, Chief Executive Officer, commented, "I'm pleased to report solid third quarter results and the considerable progress we have made to integrate our two organizations since the transaction closed in early August. Our newly combined team has come together under the unified purpose to set the standard for infusion therapy in the alternate site setting.  While we still have a significant amount of work ahead of us, I feel we are on plan and building momentum. Through the hard work of our teams across various functions, we have developed a comprehensive plan to deliver at least $60 million in net synergies and I'm excited about all the opportunities at hand for our combined company."

Third Quarter 2019 Financial Highlights

Please note that all financial data disclosed below, as well as in the forthcoming 10-Q, is comprised of the results of legacy Option Care and its affiliates and incorporate BioScrip results from August 6, 2019 prospectively. Thus, comparisons to historical periods are relative to legacy Option Care and its affiliates only.

  • Net revenue of $615.9 million, up 24.7% compared to $493.9 million in the third quarter of 2018
  • The deduction for bad debt and contractual adjustments embedded in net revenue (presented consistent with ASC 606) represented 3.9% of gross revenue, compared to 2.8% in the third quarter of 2018
  • Gross profit of $137.8 million, 22.4% of net revenue, up 27.3% compared to $108.2 million, 21.9% of revenue, in the third quarter of 2018
  • Net loss of $42.8 million, or $0.07 per share, compared to net income of $1.8 million, or $0.00 per share, in the third quarter of 2018
  • Adjusted EBITDA of $34.8 million, up 32.1% compared to $26.3 million in the third quarter of 2018
  • Cash used in operations of $5.8 million impacted by integration and merger-related outflows, as well as higher disbursements to remediate legacy BioScrip vendor balances
  • Cash balances of $52.8 million at the end of the third quarter and no outstanding borrowings on the Company's $150 million revolver

Conference Call

The conference call can be accessed by dialing (866) 360-3136 for U.S. participants, or (602) 563-8603 for international participants, and referencing conference ID 9661889; or via a live audio webcast that will be available online at A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Option Care Health

Option Care Health (NASDAQ:BIOS), is the largest independent provider of home and alternate site infusion services in the United States.  With over 6,000 teammates, including approximately 2,900 clinicians, we work compassionately to elevate standards of care for patients with acute and chronic conditions in all 50 states.  Through our clinical leadership, expertise and national scale, Option Care Health is reimagining the infusion care experience for patients, customers and employees. To learn more, please visit our website at

Investor Contacts

Mike Shapiro      Bob East, Asher Dewhurst, Jordan Kohnstam
Chief Financial Officer  Westwicke
T:  (312) 940-2538 T:  (413) 213-0500   

Forward-Looking Statements – Safe Harbor

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include, among others, statements we may make regarding future revenues, future earnings, regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.            

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) changes in laws and regulations applicable to our business model; (ii) changes in market conditions and receptivity to our services and offerings; (iii) results of litigation; and (iv) the loss of one or more key payers. For a detailed discussion of the risk factors that could affect our actual results, please refer to the risk factors identified in our reports as filed with the SEC.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (GAAP), the Company is also reporting Adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company's liquidity. In addition, the Company's definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, stock-based compensation expense, and restructuring, acquisition, integration and other expenses. As part of restructuring, integration and other expenses, the Company may incur significant charges such as the write down of certain long−lived assets, temporary redundant expenses, professional fees, potential retention and severance costs and potential accelerated payments or termination costs for certain of its contractual obligations. Management believes that Adjusted EBITDA provides useful supplemental information regarding the performance of Option Care Health's business operations and facilitates comparisons to the Company's historical operating results. For a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see the attachment to this earnings release.  

(IN THOUSANDS)        
  September 30,   December 31,  
   2019    2018  
Cash and cash equivalents $ 52,789     $ 36,391  
Accounts receivable, net   336,303       310,169  
Inventories   109,235       83,340  
Prepaid expenses and other current assets   46,919       37,525  
Total current assets   545,246       467,425  
Property and equipment, net   131,982       93,142  
Intangible assets, net   395,078       219,713  
Goodwill   1,419,373       632,469  
Other noncurrent assets   90,246       15,462  
Total noncurrent assets   2,036,679       960,786  
TOTAL ASSETS $ 2,581,925     $ 1,428,211  
Accounts payable $ 213,149     $ 187,886  
Other current liabilities   106,519       52,111  
Total current liabilities   319,668       239,997  
Long-term debt, net of discount, deferred financing costs, and current portion   1,259,460       535,225  
Other noncurrent liabilities   81,115       50,164  
Total noncurrent liabilities   1,340,575       585,389  
Total liabilities   1,660,243       825,386  
STOCKHOLDERS' EQUITY   921,682       602,825  


    Three Months Ended   Nine Months Ended
View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at